Merck (MRK) Announces Letermovir Phase 3 Met Primary Endpoint in Bone Marrow Transplant Patients
Tweet Send to a Friend
Merck & Co., Inc. (NYSE: MRK) announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
